Ikena Oncology Inc. and Inmagene Biopharmaceuticals have announced the successful completion of a $75 million private placement following their merger. The financing round included participation from a syndicate of existing and new investors such as Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors including BVF Partners L.P., Blue Owl Healthcare Opportunities, Omega Funds, and OrbiMed. This strategic funding supports the newly formed company, ImageneBio, Inc., as it continues to advance its clinical trials and expand its operations. Following the merger and financing, ImageneBio is set to begin trading on Nasdaq under the ticker symbol "IMA" on July 28, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.